Summary
DexCom, Inc. (DXCM) reported its second-quarter results for the period ending June 30, 2025, demonstrating continued revenue growth and improved profitability. For the three months ended June 30, 2025, the company generated $1.16 billion in revenue, a 15% increase year-over-year, driven by robust sales volume of its disposable sensors and a growing global customer base. Gross profit saw a 10% increase to $688.8 million, though the gross profit margin slightly decreased due to inefficiencies in supply availability, build configurations, and product mix. Operating income significantly improved by 35% to $212.6 million, reflecting strong revenue growth coupled with a decrease in selling, general, and administrative expenses, partly due to lower legal costs. Net income for the quarter rose by 25% to $179.8 million, resulting in diluted earnings per share of $0.45. The company maintained a strong liquidity position, ending the quarter with $2.93 billion in cash, cash equivalents, and short-term marketable securities. Management is focused on product innovation, global expansion, and strategic partnerships, while also navigating regulatory considerations, including an FDA warning letter received in March 2025.
Financial Highlights
49 data points| Revenue | $1.16B |
| Cost of Revenue | $468.30M |
| Gross Profit | $688.80M |
| R&D Expenses | $148.20M |
| SG&A Expenses | $328.00M |
| Operating Expenses | $476.20M |
| Operating Income | $212.60M |
| Interest Expense | $3.80M |
| Net Income | $179.80M |
| EPS (Basic) | $0.46 |
| EPS (Diluted) | $0.45 |
| Shares Outstanding (Basic) | 392.10M |
| Shares Outstanding (Diluted) | 408.20M |
Key Highlights
- 1Revenue increased by 15% to $1.16 billion for the three months ended June 30, 2025, compared to the prior year, driven by higher sales volume of disposable sensors.
- 2Operating income surged by 35% to $212.6 million, indicating improved operational efficiency and revenue leverage.
- 3Net income grew by 25% to $179.8 million, with diluted EPS at $0.45, showcasing enhanced profitability.
- 4Gross profit margin experienced a slight decline due to supply chain inefficiencies and product mix changes, despite an overall increase in gross profit.
- 5Selling, general, and administrative expenses decreased by 1% due to lower legal expenses, partially offset by increased compensation costs.
- 6The company ended the quarter with a strong cash and marketable securities balance of $2.93 billion, providing ample liquidity.
- 7DexCom received an FDA warning letter in March 2025 concerning manufacturing processes and its quality management system, which it is actively addressing.